TABLE 1

Pharmacology of (+) and (−)-MBP at human (h) and mouse (m) 5-HT2 receptors

Ki values (nM) were determined by displacement of [3H]5-HT (agonist labeled), [3H]ketanserin (5-HT2A), or [3H]mesulergine (5-HT2B, 5-HT2C) (antagonist labeled). Function values were determined by an inositol phosphate hydrolysis assay that measured the 5-HT2-mediated activation of phospholipase C. The pA2 value was determined from competitive antagonism functional assays with 5-HT. All data were from HEK cells transiently expressing one of the three 5-HT2 receptors. Data represent the mean (± S.E.M.) from at least three independent experiments.

CompoundIn Vitro Pharmacologyh5-HT2Ah5-HT2Bh5-HT2Cam5-HT2Am5-HT2Ca
(−)-MBPKi antagonist labeled20 (4.5)13 (5.2)12 (2.8)26 (2.3)11 (2.5)
Ki agonist labeled77 (14)199 (35)9.1 (0.5)Not testedNot tested
FunctionpA2 = 2.64 (0.05)IC50 = 112 (24)EC50 = 19 (3)No activation @ 10 μMEC50 = 115 (4)
Efficacy (%)No activation @ 10 μM69 (5) (inverse agonist)b63 (13) (agonist)cNo activation @ 10 μM60 (1) (agonist)c
(+)-MBPKi antagonist labeled332 (42.1)31 (7.1)200 (24.1)534 (63.0)969 (77.5)
FunctionEC50 > 1000EC50 > 1000EC50 > 1000EC50 > 1000EC50 = 122 (9.0)
Efficacy (%)34 (4) (agonist)c42 (6) (agonist)c81 (8) (agonist)c30 (5) (agonist)c57 (10) (agonist)c
  • a h5-HT2C, human 5-HT2C-ini isoform; m5-HT2C = mouse 5-HT2C-vnv isoform.

  • b For efficacy, the percentage of basal signaling (inverse agonism).

  • c For efficacy, the percentage of maximal 5-HT response (agonism).